CelltrionHealthcare
MENU
History
Celebrating the beginning of the biosimilar era When the biosimilar industry was newly emerging, Celltrion Healthcare established strategic relationship with Celltrion as co-developer with strong conviction that the biosimilar business would be successful. In 2013, Remsima®, the world’s first biosimilar monoclonal antibody, was launched in Europe that led the global pharmaceutical market, bringing the significance of biosimilars to worldwide attention.
- 1999.12
- Established Nexol Inc
- 2008.08
- Established Global distribution agreement with Celltrion
- 2009.03
- Changed the company name to Celltrion Healthcare
- 2013.09
- Launched Remsima® in Europe
Proving the potential success of biosimilars The total cumulative export value of Remsima® reached KRW 1 trillion in 2016, which was a great achievement in the biopharmaceutical history of Korea. In addition, Celltrion Healthcare managed to launch Remsima®(Inflectra®) in the United States, which is known for having the world’s top pharmaceutical market, and Truxima®, the world's first oncology mAB biosimilar, in Europe, proving that biosimilars have the potential for success in the global markets.
- 2015.12
- Won the “USD 30 Billion Trade Award” at the 52nd Annual Trade Day
- 2016.10
- The total export value of Remsima® reached KRW 1 trillion
- 2016.12
- Launched Remsima®(Inflectra®) in the United States
- 2017.04
- Launched Truxima® in Europe
- 2017.06
- Celltrion Healthcare listed on KOSDAQ
- 2017.12
- The market share of Remsima® bypassed that of the originator medicine as a biosimilar for the first time in Europe.
Becoming the world’s leading bio-company The biosimilar market has led the global healthcare industry and been recognized for its financial value and growth potential. Celltrion Healthcare, which brought success to biosimilars, is now taking a bold step into becoming a direct seller of pharmaceuticals to the world.
- 2018.05
- Launched Herzuma® in Europe
- 2019.11
- Launched Truxima® in the United States
- 2019.11
- RemsimaSC® is approved by Europe (EMA)
- 2020.02
- Launched RemsimaSC® in Europe
- 2020.03
- Launched Herzuma® in the United States
